By Justin Petrone

After years of serving the life science research market, Roche NimbleGen is now preparing for its entry into the molecular testing space with an initial focus on the diagnosis of genetic abnormalities. At the same time, it is looking at developing tests for other indications, such as in oncology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.